4月20日,葛兰素史克宣布,国家药品监督管理局已批准注射用玛贝兰妥单抗(商品名:倍乐锐)与硼替佐米和地塞米松的联合治疗方案,用于既往接受过至少一线治疗的多发性骨髓瘤成年患者。该联合治疗方案的上市申请已被纳入优先审评审批程序,并被纳入突破性治疗药物程序。 多发性骨髓瘤是全球第三大常见的血液癌症,通常被认为是可治但不可治愈的疾病。在过去三十年间,中国多发性骨髓瘤的发病率已翻倍,每年新增病例约...
Source Link4月20日,葛兰素史克宣布,国家药品监督管理局已批准注射用玛贝兰妥单抗(商品名:倍乐锐)与硼替佐米和地塞米松的联合治疗方案,用于既往接受过至少一线治疗的多发性骨髓瘤成年患者。该联合治疗方案的上市申请已被纳入优先审评审批程序,并被纳入突破性治疗药物程序。 多发性骨髓瘤是全球第三大常见的血液癌症,通常被认为是可治但不可治愈的疾病。在过去三十年间,中国多发性骨髓瘤的发病率已翻倍,每年新增病例约...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.